Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice presentation on 038 and also the newer 039.
I also don't understand why, if Marker can add up to 11 antigens (from 5), and already did the pre-clinical work (they said on 3-28), why they didn't do a more targeted cocktail for pancreatic cancer.
What really perplexes me is Marker as a stock, and it's current stock price, (you mentioned buying 10 or 20 shares).
You mention ALLO with a market cap of 3.6 billion and a pipeline that is mostly pre-clinical (behind Markers).
And FATE with a market cap of 1.1 billion and a pipeline that is mostly pre-clinical (behind Markers).
Then Cellectis with a market cap of 800+ million and a pipeline that is mostly pre-clinical (behind Markers).
And consider the many billions that KITE and JUNO got bought out for.
Markers 240 million market cap seems awful cheap to me considering their MultiTAA potential and their pipeline.
Comments (gleaned info) about/from March 28 biz update.
It was said that about one month from March 28 (about now), MRKR was having a FDA meeting concerning Pre-IND (investigational new drug) application, and with post transplant AML there was virtually no other available therapy so for those in the study who do not get the MRKR therapy, they would get "standard of care" which would be nothing more than "observation", in other words "nothing".
If that is the case, then efficacy or positive results compared to "observation" or "nothing" should be a pretty easy endpoint to beat by a mile I would think.
Concerning the pancreatic trial info that was going to be presented at ASCO, two observations.
First, even though there are 30 patients enrolled, at ASCO they only would have presented data from just a few patients because the patients have to progress along timewise before they can have any meaningful data to present, ie: six rounds of chemo or whatever, so it may just be better off that they missed ASCO and present/release that data in a few months when they have a larger patient base to report on.
Also, something was said in a round about way that I think was telling.
It was asked, why the pancreatic patients increased so quickly over a short period of time from December.
Although it was really not answered directly, it was said that MultiTAA is not as well known as CAR-T (bad for now), but it was also said that patients and clinicians (Doctors) tend to be well read and informed and when they get a hint or whiff of efficacy or success, they gravitate toward that efficacy.
So it would seem that there was a whiff of success in the MRKR pancreatic trial that got out to clinicians (good).
One more bit of info that was said about solid tumors and other cancers.
For CAR-T and other non-MRKR therapies, it can take a year or more and a lot of money to develop a new approach or let's say a new medicine to start a trial for.
MRKR said that although for Multi-TAA it might take a month, for solid tumors and other cancers it would take MRKR NO TIME AT ALL because all the pre-clinical work has ALREADY BEEN DONE to add several more peptide antigens to their current therapy, and they can add/increase from five up to eleven antigens to expand their target repertoire for other possible cancer targets, and they said they can "do that today if they choose to".
So having said all of that, WHY are there 4 million shares shorted ???
https://www.markertherapeutics.com/wp-content/uploads/2019/03/MarkerTherapeutics_20190328_500PME.mp3
When I think of all these shorts, I am reminded of a song from 1963 released by RUBY & THE ROMANTICS.
OUR DAY WILL COME … and then the shorts will be screwed.
Shorts up to over 4 million shares.
When they all have to cover it will be funny.
Remember, 3 million of those shares were shorted under $7.
MRKR - killer Multi-TAA technology.
1/10th the cost of Car-T in 1/4 the timeframe.
300 million market cap sitting on 10 - 12 billion tech when you consider what Juno and Kite got bought out at.
MRKR - killer Multi-TAA technology.
1/10th the cost of Car-T in 1/4 the timeframe.
300 million market cap sitting on 10 - 12 billion tech when you consider what Juno and Kite got bought out at.
Yeah, I guess it was good for Moleculin.
It just upsets me because we (MRKR) have very good success with several diseases in HUMANS …. nothing.
They have a success with a mouse …. and the stock triples.
There is definitely a lot SELLING pressure and not much BUYING pressure.
Why do I say that.
I've been short term trading in nice round numbers, ie: 1000 or 2000 shares per each order.
When I BUY (which means others are selling), it is done in one trade, 1000 shares per order.
BUT, when I SELL (which needs others to buy), it takes numerous trades like this:
Filled Sell 16 MRKR Limit 5.57 10:14:56 04/22/19
Filled Sell 218 MRKR Limit 5.57 10:14:56 04/22/19
Filled Sell 100 MRKR Limit 5.57 10:14:56 04/22/19
Filled Sell 50 MRKR Limit 5.57 10:14:56 04/22/19
Filled Sell 196 MRKR Limit 5.57 10:14:56 04/22/19
Filled Sell 420 MRKR Limit 5.57 10:14:56 04/22/19
BUT THE BUYS:
Filled Buy 1000 MRKR Limit 5.07 09:51:54 04/23/19
There is just no buying pressure from individuals or institutions.
You would THINK that at least institutions would be loading up at these cheap prices????
I just DO NOT understand it.
So just for yucks, I just tripled down on my OTA (one triggers another) orders, so instead of 2 open OTA's, I got 6 open OTA's, varying price ranges, 5.07-5.57, 5.05-5.60, 4.75-5.45.
Feel free to play along.
Can someone explain how this is legal?
OK, Last Wednesday 4-17, Moleculin Announces Significant Discovery in Lung Cancer Models (very early mouse models), and the next day 4-18, Moleculin Biotech Gets FDA Fast Track Designation for Annamycin.
Stock goes from $1.00 to $1.40 - OK that makes sense.
THEN, yesterday, Moleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019.
NOW, the conference call (tomorrow) will discuss WHAT THEY ALREADY ANNOUNCED on 4-17 and 4-18.
And yesterday. for some idiotic reason, the stocks goes up to past $3.00 … because of 2 reasons, #1 people who thought this was NEW news and didn't realize they already announced it last week, and #2 momentum players, the trend is your friend.
Today, stock dumps back down to 1.59.
OK, NOW, here is the part I question the legality of.
TODAY, Moleculin Announces $15.0 Million Registered Direct Offering, of 9,375,000 units at a public offering price of $1.60 per unit in a registered direct offering. Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock.
HOW is it legal for the company ITSELF to artificially raise the stock price with a bogus announcement that they ALREADY made several days before and then take advantage of that higher price in order to have a stock offering at a price higher than the stock would have otherwise been?
It seems to me that the stock offering was planned before hand, they made their FIRST announcements on 4-17 and 4-18, but the stock did not go as high as they hoped, so they make a second bogus announcement to drive the stock price higher. How is that legal?
Sold them yesterday at 5.57, bought them all back this morning at 5.07.
Next order, sell them at 5.57.
Rinse and repeat (just the "trade" shares), not the long term hold shares.
$1000+ here, $1000+ there, they're playing the game, why not play along and make extra $'s.
Follow up to post 26200. The recently bought shares, sold this morning at 5.57. Next order, buy them back at 5.07.
Rinse and repeat, if THEY are playing the low 5's to low 6's game, I might as well just play along.
Sounds good to me - “With promising early clinical results in multiple cancer indications, we believe our therapies may represent the next major leap forward in cell therapy for cancer,” said Peter L. Hoang, President and CEO of Marker Therapeutics.
This just started in March 2019 when OutcomeRx and Vineti announced a new alliance to build patient-centered digital and services solutions to streamline cell and gene therapies.
One month later, Marker taking advantage of it, GREAT. If it helps us do trials faster, better, more efficiently, and produces better results, sounds good to me.
Phase 2 trial with the Mayo Clinic.
Phase 2 trial with Memorial Sloan Kettering.
Phase 2 trial with Baylor College of Medicine.
A (seemingly) promising Phase 1/2 Baylor trial (pancreatic cancer).
A Nobel prize winner.
Backers with good track records like NEA and Baker.
Yeah, this company sucks.
I guess maybe when we also have trials with M D Anderson and St. Jude we will get noticed.
Wish there was more buying for accumulation. Today's very light 220,000 shares volume I would have thought would be MUCH heavier volume given that the price is near the lows.
One can't really say it is because there are no shares being offered to sell … because …
the shares I bought yesterday at 5.05, I've got an open sell limit 5.60, the price has been up to 5.56 today, so if there was any serious accumulation at these low bargain prices, surely someone accumulating would be willing to pay 5.60 if they were willing to pay 5.56.
OK Thanks, waiting on AACR in July and ESMO in September.
Still trading on the side in the meantime though.
That is EXACTLY what I'm upset about.
If there is only one thing a cancer company does NOT want to screw up, it is the only one shot per year ASCO meeting.
"The abstract was submitted under the TIP (Trials in Progress) track. Abstracts submitted under the TIP track cannot include new clinical data. They can only reference data that has already been presented."
THEY SHOULD HAVE KNOWN THAT and submitted it the correct way under the correct category.
OK Phantom, Thanks again. I just think that they (whoever) should have either presented the abstract in a form that would have been accepted, OR they should have know because of ASCO regs that what they wanted to present WOULD be rejected in advance and not put all of us through this hoping on ASCO game.
Phantom, this low 5's to low 6's stock price, back and forth tennis game that MRKR has been playing for MANY MONTHS is now going to continue.
The shares I bought this morning at 5.05 ...
Now, let me stop for a second and say:
I am NOT selling any shares I owned yesterday that are long term holds,
And I'm NOT suggesting that anybody sell their own long term hold shares,
BUT, the shares I bought this morning at 5.05, I'm not even waiting for $6+. I just put in another OTA (one triggers another) order:
Sell (this mornings bought shares) limit $5.60, then
Buy (the same amount) limit $5.10.
And I am going to jump in with the Market Makers and ride along and play their game, over and over and over, as many times as it works.
Still holding my long term shares, but if I can make an extra $1000+ over and over while I wait for the hoped for great news, I'll just trade playing whatever game whoever is playing with this up and down (like clockwork) stock price oscillations.
It kind of sucks that we have to rely on an investor (YOU) to get accurate news instead of the company where it is supposed to be coming from.
This has been a pattern for years and it's getting kind of old.
Would like Phantom to give an update and opinion on todays events … as my plan backfired.
I had an OTA (one triggers another) order to buy at 5.27, which would trigger the next order to buy at 5.05.
Well, both orders got executed at 5.05 at the open this morning.
Both orders being filled at 5.05 was good, that's not the backfire part.
I was hoping to buy more cheap before the news that we were accepted for ASCO, which would (I hoped) raise the share price.
Oh well, that didn't work out.
This company, SERIOUSLY, has to tell us what is happening, news/presentations/results wise, and when for the next several months.
Nothing for nothing, but if we don't hear meaningful news, as soon as MRKR hits $6.00>, I'm selling what I just bought this morning as 5.05.
I already had too much before this mornings buy.
ASGCT - American Society of Gene & Cell Therapy - April 29 - May 2
ASCO - American Society of Clinical Oncology - May 31 – June 4
Don't know what is being presented where, but we're supposed to know about ASCO tomorrow.
I hope we present at BOTH meetings.
Besides the original TPIV shares I owned for many years, in the past 12 months bought more at 7.07, 6.58, 6.06, 5.57, and 5.05. Already own way more than I originally intended to (even after the merger news). I don't want to help push it down, but I always try to get it cheaper than last time. I REALLY don't think we will see below 5.05 again (I HOPE), but if I can't get more in the low 5's, I'll stick with current holdings.
Even though I bought more in early Feb. at 5.05 and normally wouldn't buy more unless the price was a good deal lower, just in case it drops more from here before news, I got in buy at 5.27. We'll see.
OooKkk?
On 12-31-18, 1.1 million shares were shorted … and we were selling at $7.20.
Now there are 3 million shares shorted (almost 3 times the amount) … and we have traded BELOW $7.20 the Entire Time.
So, there is no doubt that almost 2 million shares were shorted BETWEEN $6 and $7.
One little tiny bit of good news, any tiny tidbit that makes it pop to $8, is just going to blow 2 million shorts right out of the water.
Any price above $7.20, and they are losing money.
Geez, if that were me, and I had that small of a price margin before I was losing money, I'd be Very Nervous.
I'm sure they already have their orders in to cover at just below their loss price, around $6.50, or whatever it needs to be.
I also think that, SINCE 12-31-18, EVERY TIME the price has started to creep up to their $6.50 (or whatever) cover price, They have been supporting their cover price by Shorting More.
This WILL backfire on them.
No Doubt, at some point, (and I think one tiny bit of good news soon some point), THIS WILL BACKFIRE ON THEM.
When I first read about 4-15 lockup, I asked, who, what owners would sell? And then who, what owners would sell at $6.
I could see some selling if we were at $20, profit taking for safety, or someone wants to buy a new car or home, etc.
And even if there was selling, you would think that Vanguard or T Rowe Price or Janus would be there to snap up any sold shares.
I guess we will see in the next couple of weeks.
I'm just waiting on ASCO developments.
Thanks PL for info/insight/calmness.
Opinions? I've been reading everybody's posts from the last few days and there seems to be some new info (?).
If I understood correctly, in 10 days, on April 15th, a stock lockup period is over, so, in theory that may lead to selling? But, would that also be better over the medium/long term because it would put more shares out and MRKR would have more liquidity?
Anybody know about how many more shares will be liquid?
Also, read that in December we had 3 pancreatic patients, but now we have (at least) 30, but maybe as many as 45 (full enrollment).
Wouldn't that indicate that they must have had great success early on in order for so many additional patients to be enrolled in such a short period of time?
I don't even know … are Doctors allowed to tell other Doctors about successes (before they are reported)?
$5.95 … just CRAZY!
Sometimes I ask myself if we are all just wrong about MRKR.
Then I look at all of the facts, nothing but positive news so far. We know MultiTAA has NOT shown all the negative side effects that CAR-T has shown (some of which kill patients).
Smart scientists, smart management, Nobel Prize, Baylor, ect. ect.
If I have "Marker derangement syndrome", I am not aware of it.
"That means the shorted % of available shares in now ~ 40%. The potential for a short squeeze is all the better."
YES, agree, HOPE it happens SOON.
From Crypto Amber article on 4-1-19.
"Analyst Insight on Marker Therapeutics, Inc. (MRKR)
MRKR has had a rough year with 18.92% up on its year to date chart, also jumping by 6.11% during the course of the last 30 days. However, Wall Street seem to be interested in MRKR stock as investors are getting bullish on the stock. According to analysts, it could reach the price target of $11.63 price target, predicting a surge by 155.81% starting from the most recent close at its low. For now, MRKR shares are trading around -51.29% down when compared to its 52-week high price."
At 3:40 we were negative, ended the day up a bit. Lately seems to be buys at end of day. I can only see that as a good sign. As long as we just keep chugging up, bit by bit.
It's Monday, April 1st.
Can we PLEASE make the shorters look like fools today?
To follow up, and I know this is going to sound crazy, and this also follows the discussion about "right to try".
If I ever got ANY type of cancer, even if it's a cancer that Marker is not working on, the first place I'd like to go to is to Marker and say "do what you do and shoot me up with it" because I want epitome spreading and as many anti-tumor, anti-cancer antigens as I can get.
It's one of the indications they are targeting in their pipeline, but not the main focus, kind of under the radar.
If they have great news at ASCO concerning pancreatic cancer, it will be big, and will be bigger as it represents a potential treatment for many other solid tumors and even other types of cancers.
Yes, I liked the last couple of days. $6.03 to $6.65, 1.3 million shares today.
I've said it a couple of times before (and I was wrong because it did not happen), BUT,
Just a couple of more days like today, Mon, Tues, and we will start a short squeeze which will forced the price even higher.
We can do it. Close Mon at $7.25, close Tues at $7.75.
Wed it will hit $9, … and then the shorts will pile in and bring it back down to ???, just so they can get burned again (I HOPE).
It was used even before it became law, it was called "compassionate use" and "expanded access" if I recall correctly.
The first patient dosed under right to try was in 2017.
https://www.raps.org/news-and-articles/news-articles/2019/1/first-patient-treated-under-right-to-try-law
I tend to be Mr. Conservative on things like future price targets, so I'll say, IF.
IF, IF we get very good ASCO presentation, we could be 500 million by June.
Then IF, IF we get a good update or two, 700M, 800M, and maybe higher by end of 2019.
PPS is like a rubber band being stretched one way or the other.
It is almost never correct, it is always stretched TOO MUCH one way or the other based on peoples emotions, greed and fear.
Right now we are stretched way TOO LOW.
We are waiting for the next "news".
You know what we really need?
We need a few people to use Marker as "right to try" and get cured.
It won't be FDA, but word of cures will get out and many other will flock to Marker for help.
The problem is, MOST doctors do not know about this.
I asked my Doctor who is an Internist. He knew CAR-T, never heard of this.
His daughter is an Oncologist, knew CAR-T, never heard of this.
We, and sick patients need JAMA, The Journal of the American Medical Association, and other medical publications to start to inform Doctors and the public.
Thank You, still don't understand why (even before) but especially after todays report, people ain't jumping on the bandwagon, but, it is what it is, I ain't going nowhere.
And NOW at 6:15 PM, the price is right back up to where it was this morning.